Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05846230




Registration number
NCT05846230
Ethics application status
Date submitted
26/04/2023
Date registered
6/05/2023
Date last updated
19/11/2024

Titles & IDs
Public title
Clairleaf??: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
Scientific title
A Randomised, Double-blind, Parallel Group, Roll-over Study Evaluating Long-term Safety and Efficacy of Oral Doses of BI 1291583 q.d. in Patients With Bronchiectasis (Clairleaf??)
Secondary ID [1] 0 0
2023-503290-38-00
Secondary ID [2] 0 0
1397-0017
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bronchiectasis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BI 1291583
Treatment: Drugs - Placebo matching BI 1291583

Experimental: BI 1291583 low dose arm -

Experimental: BI 1291583 medium dose arm -

Experimental: BI 1291583 high dose arm -


Treatment: Drugs: BI 1291583
Tablet

Treatment: Drugs: Placebo matching BI 1291583
Tablet
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Occurrence of treatment-emergent adverse events (TEAEs)
Timepoint [1] 0 0
up to 12 months
Secondary outcome [1] 0 0
Time to first pulmonary exacerbation from first drug administration in this trial to the end of the trial
Timepoint [1] 0 0
up to 12 months
Secondary outcome [2] 0 0
Rate of pulmonary exacerbations (number of events per person-time) over the course of this trial
Timepoint [2] 0 0
up to 12 months

Eligibility
Key inclusion criteria
* Patients who completed the treatment period in Phase II trials (1397-0012 or 1397-0013) as planned per protocol.
* Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the patient information.
* Signed and dated written informed consent prior to admission to the trial, in accordance with Good Clinical Practice (GCP) and local legislation.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Laboratory and medical examination

* Moderate or severe liver disease (defined by Child-Pugh score B or C hepatic impairment) or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3.0x Upper limit of normal (ULN) at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
* Estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula <30 mL/min at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
* An absolute blood neutrophil count <1,000/mm^3 (equivalent to <1,000 cells/µL or <10^9 cells/L) at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then).
* Any findings in the medical examination and/or laboratory value assessed at Visit 1 (or at the last safety assessment in the parent trial, concerning the lab tests, if no more than 6 weeks passed since then), that in the opinion of the investigator may put the patient at risk by participating in the trial.

New concomitant diagnosis and therapy

* A new diagnosis of

* Hypogammaglobulinemia
* Common variable immunodeficiency
* a1-antitrypsin deficiency being treated augmentation therapy
* Allergic bronchopulmonary aspergillosis being treated or requiring treatment
* Tuberculosis or non-tuberculous mycobacterial infection being treated or requiring treatment according to local guidelines
* Palmoplantar keratosis; or keratoderma climactericum
* Hypothyroidism, myxedema, chronic lymphedema with associated hyperkeratosis of the skin, acrocyanosis. If a subject has hypothyroidism but is treated and compensated, the subject is allowed into the trial
* Psoriasis affecting palms and soles; or body surface area for psoriasis =10%
* Reactive arthritis (Reiter's syndrome); keratoderma blennorrhagicum
* Pityriasis rubra pilaris
* Atopic dermatitis affecting palms and soles; or body surface area for atopic dermatitis =10%
* Active extensive verruca vulgaris, as per investigator's discretion
* Active fungal infection of hand and/or feet not adequately treated and responsive to antifungal therapy, as per investigator's discretion.
* Any clinically relevant respiratory infection within 4 weeks prior Visit 2, unless recovered in the opinion of the investigator by Visit 2.
* Any acute infection requiring systemic or inhaled anti-infective therapy within 4 weeks prior Visit 2.
* Positive serological tests for hepatitis B, hepatitis C (also confirmed with ( Hepatitis C Virus ribonucleic acid test (HCV RNA))), or human immunodeficiency virus (HIV) infection, or known infection status at Visit 2. (The test results will be available after randomisation. In case the results no longer satisfy the entry criteria, these patients will be discontinued.)
* Any new evidence of a concomitant disease, such as Papillon-Lefèvre Syndrome (PLS), relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal disorders, or patients who are immunocompromised with a higher risk of invasive pneumococcal disease or other invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis), that in the opinion of the investigator, may put the patient at risk by participating in the trial.
* Received any live attenuated vaccine within 4 weeks prior to Visit 1.
* Further exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/09/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/03/2026
Actual
Sample size
Target
273
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
Macquarie University - Macquarie Park
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Lung Research Queensland - Chermside
Recruitment hospital [4] 0 0
Mater Research Institute - South Brisbane
Recruitment hospital [5] 0 0
Institute for Respiratory Health - Nedlands
Recruitment hospital [6] 0 0
Trialswest - Spearwood
Recruitment postcode(s) [1] 0 0
2109 - Macquarie Park
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4032 - Chermside
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment postcode(s) [6] 0 0
6153 - Spearwood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
Ohio
Country [6] 0 0
United States of America
State/province [6] 0 0
South Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
Belgium
State/province [8] 0 0
Gent
Country [9] 0 0
Belgium
State/province [9] 0 0
Leuven
Country [10] 0 0
Bulgaria
State/province [10] 0 0
Kozloduy
Country [11] 0 0
Bulgaria
State/province [11] 0 0
Montana
Country [12] 0 0
Bulgaria
State/province [12] 0 0
Razgrad
Country [13] 0 0
Bulgaria
State/province [13] 0 0
Ruse
Country [14] 0 0
Bulgaria
State/province [14] 0 0
Sofia
Country [15] 0 0
Canada
State/province [15] 0 0
Quebec
Country [16] 0 0
Czechia
State/province [16] 0 0
Kralupy nad Vltavou
Country [17] 0 0
Czechia
State/province [17] 0 0
Prague 9
Country [18] 0 0
Denmark
State/province [18] 0 0
Hvidovre
Country [19] 0 0
Denmark
State/province [19] 0 0
København Ø
Country [20] 0 0
Denmark
State/province [20] 0 0
Odense
Country [21] 0 0
Denmark
State/province [21] 0 0
Roskilde
Country [22] 0 0
Denmark
State/province [22] 0 0
Vejle
Country [23] 0 0
Denmark
State/province [23] 0 0
Ålborg
Country [24] 0 0
France
State/province [24] 0 0
Amiens
Country [25] 0 0
France
State/province [25] 0 0
Montpellier
Country [26] 0 0
France
State/province [26] 0 0
Rennes
Country [27] 0 0
Germany
State/province [27] 0 0
Berlin
Country [28] 0 0
Germany
State/province [28] 0 0
Essen
Country [29] 0 0
Germany
State/province [29] 0 0
Frankfurt
Country [30] 0 0
Germany
State/province [30] 0 0
Großhansdorf
Country [31] 0 0
Germany
State/province [31] 0 0
Immenhausen
Country [32] 0 0
Germany
State/province [32] 0 0
Konstanz
Country [33] 0 0
Germany
State/province [33] 0 0
Lübeck
Country [34] 0 0
Germany
State/province [34] 0 0
München
Country [35] 0 0
Germany
State/province [35] 0 0
Wiesbaden
Country [36] 0 0
Hungary
State/province [36] 0 0
Budapest
Country [37] 0 0
Hungary
State/province [37] 0 0
Pecs
Country [38] 0 0
Israel
State/province [38] 0 0
Beer Sheva
Country [39] 0 0
Israel
State/province [39] 0 0
Haifa
Country [40] 0 0
Israel
State/province [40] 0 0
Jerusalem
Country [41] 0 0
Israel
State/province [41] 0 0
Tel Aviv
Country [42] 0 0
Italy
State/province [42] 0 0
Palermo
Country [43] 0 0
Italy
State/province [43] 0 0
Pavia
Country [44] 0 0
Italy
State/province [44] 0 0
Rozzano (MI)
Country [45] 0 0
Japan
State/province [45] 0 0
Aichi, Nagoya
Country [46] 0 0
Japan
State/province [46] 0 0
Aomori, Hirosaki
Country [47] 0 0
Japan
State/province [47] 0 0
Chiba, Kamogawa
Country [48] 0 0
Japan
State/province [48] 0 0
Fukuoka, Fukuoka
Country [49] 0 0
Japan
State/province [49] 0 0
Ibaraki, Naka-gun
Country [50] 0 0
Japan
State/province [50] 0 0
Kagoshima, Kagoshima
Country [51] 0 0
Japan
State/province [51] 0 0
Mie, Matsusaka
Country [52] 0 0
Japan
State/province [52] 0 0
Osaka, Toyonaka
Country [53] 0 0
Japan
State/province [53] 0 0
Saga, Saga
Country [54] 0 0
Japan
State/province [54] 0 0
Tokyo, Kiyose
Country [55] 0 0
Japan
State/province [55] 0 0
Tokyo, Minato-ku
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Cheongju
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Seoul
Country [58] 0 0
Latvia
State/province [58] 0 0
Daugavpils
Country [59] 0 0
Latvia
State/province [59] 0 0
Jurmala
Country [60] 0 0
Latvia
State/province [60] 0 0
Riga
Country [61] 0 0
Mexico
State/province [61] 0 0
Chihuahua
Country [62] 0 0
Mexico
State/province [62] 0 0
Monterrey, Nuevo León
Country [63] 0 0
Mexico
State/province [63] 0 0
Monterrey
Country [64] 0 0
Mexico
State/province [64] 0 0
Oaxaca
Country [65] 0 0
Mexico
State/province [65] 0 0
Tlalnepantla
Country [66] 0 0
Netherlands
State/province [66] 0 0
Amsterdam
Country [67] 0 0
Netherlands
State/province [67] 0 0
Utrecht
Country [68] 0 0
Netherlands
State/province [68] 0 0
Zutphen
Country [69] 0 0
Poland
State/province [69] 0 0
Bialystok
Country [70] 0 0
Poland
State/province [70] 0 0
Piaseczno
Country [71] 0 0
Poland
State/province [71] 0 0
Swidnik
Country [72] 0 0
Poland
State/province [72] 0 0
Warszawa
Country [73] 0 0
Poland
State/province [73] 0 0
Wroclaw
Country [74] 0 0
Portugal
State/province [74] 0 0
Lisboa
Country [75] 0 0
Spain
State/province [75] 0 0
Barcelona
Country [76] 0 0
Spain
State/province [76] 0 0
L'Hospitalet de Llobregat
Country [77] 0 0
Spain
State/province [77] 0 0
Mérida
Country [78] 0 0
Spain
State/province [78] 0 0
Pozuelo de Alarcón
Country [79] 0 0
Turkey
State/province [79] 0 0
Istanbul
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Dundee, Scotland

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleaf?? or 1397-0013 Clairafly??). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term.

Participants take a low, medium, or high dose of BI 1291583 as a tablet once a day for up to 1 year. Participants who were taking placebo in the AirleafTM or ClairaflyTM study are put into the BI 1291583 dosage groups randomly, which means by chance. Placebo tablets look like BI1291583 but do not contain any medicine. Participants who were taking BI 1291583 in the AirleafTM or ClairaflyTM study continue to take the same dose.

Participants visit the study site 10 times and get 4 phone calls from the site staff. During the visits, the doctors collect information on any health problems of the participants. The doctors also check whether BI 1291583 helps reduce the symptoms of bronchiectasis.
Trial website
https://clinicaltrials.gov/study/NCT05846230
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Boehringer Ingelheim
Address 0 0
Country 0 0
Phone 0 0
1-800-243-0127
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05846230